GACM
AVDL

Green Arrow Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Green Arrow Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-25,000
Closed -$375K – 176
2014
Q2 		$375K Buy
+25,000
New +$302K 0.05% 154

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Green Arrow Capital Management's AVDL Position: Q3 2014 in Review

Green Arrow Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2014, closing a stake of 25,000 shares — an estimated $375K sold.

Green Arrow Capital Management first reported a position in AVDL in Q2 2014 and held it in 1 quarter. The position peaked at $375K in Q2 2014. 71 funds tracked by Wall St. Rank hold AVDL as of Q3 2014.

  • Green Arrow Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Green Arrow Capital Management sold 25,000 Avadel Pharmaceuticals shares in Q3 2014, an estimated $375K.
  • Green Arrow Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Green Arrow Capital Management's Avadel Pharmaceuticals position peaked at $375K in Q2 2014.
  • 71 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2014.

Based on Green Arrow Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.